Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Pseudohypoparathyroidism or Albright Hereditary Osteodystrophy
and you are
between 13 and 99
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight loss, improve glucose tolerance and slow growth plate closure in children and young adults.

Provided treatments

  • Drug: Theophylline
  • Drug: Placebos
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03029429. The sponsor of the trial is Vanderbilt University Medical Center and it is looking for 34 volunteers for the current phase.
Official trial title:
Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism